Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content. **Bone-Targeted Therapies and Other Emerging Radiopharmaceuticals**

> Oliver Sartor, MD Laborde Professor for Cancer Research Depts. of Medicine and Urology Medical Director, Tulane Cancer Center Tulane Medical School New Orleans, LA

Disclosures


Advisory Committee	Bayer HealthCare Pharmaceuticals, EMD Serono Inc, Fusion Pharmaceuticals
Consulting Agreements	Advanced Accelerator Applications, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Endocyte Inc, Hinova Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Myovant Sciences, Pfizer Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme
Contracted Research	AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Innocrin Pharmaceuticals Inc, Invitae, Johnson & Johnson Pharmaceuticals, Merck, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, SOTIO LLC
Data and Safety Monitoring Board/Committee	AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Myovant Sciences, Pfizer Inc
Ownership Interest	Lilly

Based on available data and your own clinical experience, do you believe that radium-223 relieves pain?


Have you observed an improvement in bone pain in any patient receiving radium-223?

	Pain relief	Observed bone-pain improvement		
EMMANUEL S ANTONARAKIS, MD	Yes	Yes		
A OLIVER SARTOR, MD	Yes	Yes		
HOWARD I SCHER, MD	Yes	Yes		
MATTHEW R SMITH, MD, PHD	No	No		
CORA N STERNBERG, MD	Yes	Yes		

How frequently does treatment with radium-223 lead to clinically relevant cytopenias?



A patient who previously received sipuleucel-T now has progressive bone-only metastases and moderate pain in multiple locations, none of which requires immediate radiation therapy. The patient is being started on secondary hormonal therapy (eg, enzalutamide, abiraterone). Would you recommend adding radium-223?



Radiation comes in many forms

- External beam
 - Fractionated, hypofractionated, SBRT
- Radiopharmaceuticals
 - Betas and Alphas
 - Bone targeted, tissue targeted (small molecules and antibodies)
- Brachytherapy
 - HDR and LDR
- Selective Internal Radiation Therapy (SIRT)
 - Y90 microspheres

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JULY 18, 2013

VOL. 369 NO. 3

Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

C. Parker, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O'Sullivan, S.D. Fosså, A. Ch A. Widmark, D.C. Johannessen, P. Hoskin, D. Bottomley, N.D. James, A. Solberg, S. Boehmer, M. Dall'Oglio, L. Franzén, R. Coleman, N.J. Vogelzang, C.G J. Garcia-Vargas, M. Shan, Ø.S. Bruland, and O. Sartor, for the AL

🔀ki, P. Wiechno, J. Logue, M. Seke, dikus, J. Kliment, S. Wedel,

No abiraterone and no enzalutamide

Can Radium add value to Abiraterone or Enzalutamide in Bone-Metastatic CRPC? Two large trials


- Abiraterone +/- radium phase III (ERA 223)
 - Data monitoring committee (DMC) stopped the trial
 - Unblinded for safety

Enzalutamide +/-radium phase III (PEACE III) trial underway
 DMC has not stopped the trial

Clinicaltrials.gov, Accessed February 14, 2019 (NCT02043678) Clinicaltrials.gov, Accessed February 14, 2019 (NCT02194842)


ERA 223:Abiraterone+Prednisone or Prednisolone +/- Radium-223

// Patient not like ALSYMPCA (NCT00699751): asymptomatic, chemotherapy-naïve
// Radium-223 starting at same time as abiraterone and prednisone
// Conducted in North America, Europe, Asia, Australia, Brazil, and Israel at 168 sites.



Smith M et al. ESMO 2018 Abstract LBA30

ERA 223 Stopped Early by IDMC for Adverse Findings: Fracture and Survival



www.ema.europa.eu; EMA/170170/2018

ERA 223 Stopped Early by IDMC for Adverse Findings: Fracture and Survival




Table 2. Primary cause of death (safety analysis set)							
	Progressive	Radium-223 +Abi/Pred N=392 (100%)	Placebo +Abi/Pred N=394 (100%)				
Number (%) of deaths	disease	136 (34.7%)	111 (28.2%)				
Primary cause of death Progressive disease93 (23.7%)76 (19.3%)Adverse event associated with clinical disease progressionb13 (3.3%)12 (3.0%)Adverse event not associated with clinical disease progressionb12 (3.1%)9 (2.3%)Unknown Otherc10 (2.6%)7 (1.8%)8 (2.0%)7 (1.8%)							
Table 3. Relationship between all fractures, SSE fractures and deaths (safety analysis set)							
	Ra223+Abi/Pred (n = 392)	Placebo+Abi/Pred (n = 394)	Relative Risk (RR)/ Risk				
	(=100%)	(=100%)	difference (RD) (Ra223 vs. Plc)				
Number of deaths	136	111	RD 6.5%				
	(34.7%)	(28.2%)	RR 1.23				
Death without any prior fractures	97	99	RD -0,4%				
	(24.7%)	(25.1%)	RR 0.98				
Death with prior fractures	39	12	RD 6.9%				
	(9.9%)	(3.0%)	RR 3.27				

8

4

(2.0%)

(1.0%)

RD 3.1%

RR 2.51

RD 4.9%

RR 5.78

20

23

(5.1%)

(5.9%)

RR = 0.98 for death without fracture


www.ema.europa.eu; EMA/170170/2018

Death with prior SSE fractures

Death with prior non-SSE fractures

Bone Health Agents <u>Markedly</u> Reduce the Risk of Fractures in ERA 223 Radium-223 Arm

	Radium-223 + Abi/Pred n=155	Radium-223 + Abi/Pred n=246	Placebo Abi/Pro n=169	ed Abi/Pred
	With BHA	Without BHA	With BI	HA Without BHA
EBRT	25 (16.1%)	65 (26.4%)	32 (18.9	%) 52 (22.0%)
Symptomatic bone fracture	2 (1.3%)	37 (15.0%)	4 (2.4%	%) 11 (4.7%)
Orthopedic surgery	1 (0.6%)	9 (3.7%)	2 (1.2%	(6) 4 (1.7%)
Spinal cord compression	6 (3.9%)	5 (2.0%)	5 (3.0%	(6) 14 (5.9%)




Radium-223 Only Goes to Bone!


We need to target tumors regardless of location

PSMA binding ligands do that....

congress MADRID 2017


Peter Mac Peter MacCallum Cancer Centre Victoria Australia





PSMA-Lu-177 ready for prime time?


VISION



N=750 Alternative 1° endpoint: rPFS <u>or</u> OS

Clinicaltrials.gov, Accessed February 14, 2019 (NCT03511664)

Targeting DNA damage repair pathways with novel agents: Trials in Progress



O'Connor, Molecular Cell 60, November 19, 2015

Radio-conjugates: PSMA targeted alpha emitters (Actinium-225) as 9th line treatment

Kratochwil et a. J Nuc Med 57: 1-4, 2016

Patient A Leuprolide Zoledronate Docetaxel (50 cycles) 3x 1x Carmustine/epirubicin in 225 Ac-PSMA 225Ac-PSMA hyperthermia Abiraterone Enzalutamide ²²³Ra (6 cycles) Abiraterone reexposition Estramustine 12/2014 7/2015 9/2015 PSA = 2,923 ng/mL PSA = 0.26 ng/mLPSA < 0.1 ng/mL Thank you!!!